TER across HCMECs. A, LY333531 prevents PDBu-induced changes in barrier function during PKCβII overexpression (n=6, **P<0.05 vs vehicle). B, RFP-PKCβII translocation indicated by inverse changes in membrane versus cytosol FI. C, RFP-PKCβII distribution before and after activation. D, Rottlerin pretreatment enhances PDBu-induced TER decrease (n=4, ***P<0.001 vs vehicle).